Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
Christopher Kirkham, Group Leader in Ex Vivo Biology at IQVIA Laboratories, shared a post on LinkedIn:
“Could platelet activation become a liability for your antibody programme?
Platelet safety is often overlooked until a signal emerges during development. However, unintended interactions with platelets can have significant consequences, including platelet depletion, activation and thrombotic complications.
Early assessment of platelet binding, activation and function can help identify potential liabilities before they become costly development challenges.
At IQVIA Laboratories, we combine flow cytometry and aggregometry to provide a comprehensive ex vivo assessment of antibody-mediated platelet responses, supporting more informed candidate selection and risk assessment earlier in development.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community